115650 (MMR-162): A Phase IIIA, Randomized, Observer-Blind, Multinational Consistency Study to Evaluate the Immunogenicity and Safety of GSK Biogicals' MMR Vaccine (209762) (Priorix?) Compared to Merck & Co., Inc.'s MMR Vaccine (M-M-R?II), as a First Dos

  • Sarpong, Kwabena, (PI)

Project: Other project

StatusFinished
Effective start/end date9/9/149/8/16

Funding

  • GlaxoSmithKline Pharmaceuticals: $2,885.00